OH Pharma
Products › Growth hormone axis › CJC-1295 + DAC 5 mg
CJC-1295 + DAC 5 mg OH PharmaCJC-1295 + DAC 5 mg OH Pharma – back of vial

Growth hormone axis · File 08

CJC-1295 + DAC 5 mg

Analysis in progress

✓Sterility and endotoxins tested by Nelson Labs (Salt Lake City)

Growth hormone, GH secretagogues and GHRH analogues.

Calculate a dose →

Description

Analogue of growth hormone-releasing hormone (GHRH). The “DAC” version binds to blood albumin, which extends its action to about one week.

Studied benefits

  • Sustained increase in GH.
  • Increase in IGF-1.
  • Pulsatile GH secretion preserved despite prolonged stimulation.

Results reported in published research; they guarantee no effect and are not an indication for use.

🔬 What the research says
  • In healthy adults (Teichman et al., 2006), a single injection raised growth hormone 2- to 10-fold and IGF‑1 1.5- to 3-fold for 6 days or more.
  • A phase 2 trial was halted in 2006 after a participant died; a link to the product was never publicly established.
⚠️ Warnings and reported side effects
  • Injection-site reactions, redness and flushing, headaches.
  • Prolonged IGF‑1 elevation: long-term effects unknown.
  • Note: the certificate available for this lot covers CJC‑1295 without DAC, so it is not linked to this product.

Consult a healthcare professional before any use. If an adverse effect occurs, stop use and see a doctor.

Certificate of analysis coming soon

This product's lot is awaiting its laboratory results. The certificate will be published on this page as soon as it is received. Every new lot is sent for analysis before being published here.

Sources

  1. Teichman et al., J Clin Endocrinol Metab 2006
  2. aidsmap — trial halted (2006)
  3. Health Canada — advisory on unauthorized injectable peptides (April 2026)

For educational purposes only. This information summarizes published studies and is neither a recommendation for use nor medical advice.

← Back to products